Redmile Group LLC Sells 10,400 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Redmile Group LLC has reduced its stake in BioNTech SE by selling 10,400 shares, decreasing its holdings by 12.5% to a total of 73,071 shares, valued at approximately $6.65 million.
• BioNTech's recent earnings report revealed a loss of ($1.60) per share, missing analyst expectations, although revenue of $306.46 million exceeded forecasts significantly.
• Analysts have mixed opinions on BioNTech, with some lowering target prices while thirteen cover the stock with a "Buy" rating, highlighting an average target price of $135.80.

Redmile Group LLC lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 12.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 73,071 shares of the company's stock after selling 10,400 shares during the quarter. Redmile Group LLC's holdings in BioNTech were worth $6,654,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech in the first quarter worth $36,000. Costello Asset Management INC bought a new stake in shares of BioNTech in the first quarter worth $91,000. Goodman Advisory Group LLC bought a new stake in shares of BioNTech in the first quarter worth $105,000. Whittier Trust Co. grew its stake in shares of BioNTech by 3,846.2% in the first quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after acquiring an additional 713 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

BNTX has been the topic of several research reports. HC Wainwright dropped their price objective on shares of BioNTech from $138.00 to $136.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. The Goldman Sachs Group initiated coverage on shares of BioNTech in a report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective on the stock. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Truist Financial restated a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Finally, Bank of America upped their target price on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Stock Up 8.7%

NASDAQ:BNTX traded up $8.96 on Friday, hitting $112.46. The stock had a trading volume of 2,052,527 shares, compared to its average volume of 669,941. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The stock has a market cap of $27.04 billion, a P/E ratio of -70.29 and a beta of 1.39. BioNTech SE Sponsored ADR has a 1 year low of $81.20 and a 1 year high of $131.49. The firm's fifty day simple moving average is $109.49 and its two-hundred day simple moving average is $104.53.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm's revenue was up 102.6% on a year-over-year basis. During the same period in the prior year, the company earned ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. Analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.